ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-16Q17912
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Monoclonal Antibody Anti VEGF Ophthalmic Drugs Market Research Report 2024
BUY CHAPTERS

Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Research Report 2024

Code: QYRE-Auto-16Q17912
Report
August 2024
Pages:68
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Novartis
Coherus BioSciences

Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market

Monoclonal antibody anti-VEGF ophthalmic drugs are a class of medications specifically engineered to target and neutralize vascular endothelial growth factor(VEGF),a key protein involved in angiogenesis and vascular permeability in the eye.These drugs are administered via intravitreal injection directly into the eye to treat diseases like wet age-related macular degeneration(AMD),diabetic retinopathy,and macular edema.
The global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs include Roche, Novartis, Coherus BioSciences, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody Anti-VEGF Ophthalmic Drugs.
The Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Report

Report Metric Details
Report Name Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market
Segment by Type
Segment by Application
  • Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Roche, Novartis, Coherus BioSciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market report?

Ans: The main players in the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market are Roche, Novartis, Coherus BioSciences

What are the Application segmentation covered in the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market report?

Ans: The Applications covered in the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market report are Age-related Macular Degeneration, Diabetic Retinopathy, Other

What are the Type segmentation covered in the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market report?

Ans: The Types covered in the Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market report are Faricimab, Brolucizumab, Other

Recommended Reports

Anti-VEGF Ophthalmics

General Ophthalmic Drugs

Ophthalmic Drug Delivery

1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Overview
1.1 Product Definition
1.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type
1.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Faricimab
1.2.3 Brolucizumab
1.2.4 Brolucizumab
1.2.5 Other
1.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application
1.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (2024-2030)
1.3.2 Age-related Macular Degeneration
1.3.3 Diabetic Retinopathy
1.3.4 Other
1.4 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts
1.4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue 2019-2030
1.4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales 2019-2030
1.4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competition by Manufacturers
2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Type & Application
2.7 Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Enter into This Industry
2.8 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation and Trends
2.8.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue
2.8.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Scenario by Region
3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2019-2030
3.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2019-2024
3.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region: 2025-2030
3.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2019-2030
3.3.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2019-2024
3.3.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2025-2030
3.4 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.4.1 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)
3.4.3 North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.5.1 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)
3.5.3 Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2030)
3.6.3 Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.7.1 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)
3.7.3 Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2030)
4.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2019-2024)
4.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Type (2025-2030)
4.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2019-2030)
4.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2019-2030)
4.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2019-2024)
4.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Type (2025-2030)
4.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2030)
5.1.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2019-2024)
5.1.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Application (2025-2030)
5.1.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2030)
5.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2019-2030)
5.2.1 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2019-2024)
5.2.2 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Application (2025-2030)
5.2.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Company Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Coherus BioSciences
6.3.1 Coherus BioSciences Company Information
6.3.2 Coherus BioSciences Description and Business Overview
6.3.3 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product Portfolio
6.3.5 Coherus BioSciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Chain Analysis
7.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Mode & Process
7.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales and Marketing
7.4.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Channels
7.4.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors
7.5 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers
8 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Dynamics
8.1 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Industry Trends
8.2 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
8.3 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
8.4 Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Roche
Novartis
Coherus BioSciences
List of Tables
 Table 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) of Key Manufacturers (2019-2024)
 Table 5. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody Anti-VEGF Ophthalmic Drugs as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024) & (K Units)
 Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2019-2024)
 Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2025-2030) & (K Units)
 Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2025-2030)
 Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2019-2024)
 Table 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2025-2030)
 Table 25. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Units)
 Table 27. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Units)
 Table 28. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Units)
 Table 32. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Units)
 Table 33. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2019-2024) & (K Units)
 Table 37. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (2025-2030) & (K Units)
 Table 38. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Units)
 Table 42. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Units)
 Table 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2019-2024) & (K Units)
 Table 47. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (2025-2030) & (K Units)
 Table 48. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2019-2024)
 Table 51. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2025-2030)
 Table 52. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2019-2024)
 Table 53. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2025-2030)
 Table 54. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2019-2024)
 Table 57. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2025-2030)
 Table 58. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2019-2024)
 Table 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2025-2030)
 Table 60. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2019-2024)
 Table 61. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2025-2030)
 Table 62. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2019-2024)
 Table 63. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2025-2030)
 Table 64. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2019-2024)
 Table 67. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2025-2030)
 Table 68. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2019-2024)
 Table 69. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2025-2030)
 Table 70. Roche Company Information
 Table 71. Roche Description and Business Overview
 Table 72. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 73. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
 Table 74. Roche Recent Developments/Updates
 Table 75. Novartis Company Information
 Table 76. Novartis Description and Business Overview
 Table 77. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 78. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
 Table 79. Novartis Recent Developments/Updates
 Table 80. Coherus BioSciences Company Information
 Table 81. Coherus BioSciences Description and Business Overview
 Table 82. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
 Table 83. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
 Table 84. Coherus BioSciences Recent Developments/Updates
 Table 85. Key Raw Materials Lists
 Table 86. Raw Materials Key Suppliers Lists
 Table 87. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List
 Table 88. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers List
 Table 89. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Trends
 Table 90. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
 Table 91. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
 Table 92. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
 Table 93. Research Programs/Design for This Report
 Table 94. Key Data Information from Secondary Sources
 Table 95. Key Data Information from Primary Sources
 Table 96. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
 Figure 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Type: 2023 & 2030
 Figure 4. Faricimab Product Picture
 Figure 5. Brolucizumab Product Picture
 Figure 6. Brolucizumab Product Picture
 Figure 7. Other Product Picture
 Figure 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (2024-2030) & (US$ Million)
 Figure 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Application: 2023 & 2030
 Figure 10. Age-related Macular Degeneration
 Figure 11. Diabetic Retinopathy
 Figure 12. Other
 Figure 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size (2019-2030) & (US$ Million)
 Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (2019-2030) & (K Units)
 Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit) & (2019-2030)
 Figure 17. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Report Years Considered
 Figure 18. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2023
 Figure 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2023
 Figure 20. Global 5 and 10 Largest Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in 2023
 Figure 21. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 23. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)
 Figure 24. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2030)
 Figure 25. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 26. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 27. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)
 Figure 28. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2030)
 Figure 29. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. U.K. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 33. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 34. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2019-2030)
 Figure 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2019-2030)
 Figure 36. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. China Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 42. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)
 Figure 44. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Argentina Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 47. Colombia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 48. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2019-2030)
 Figure 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2019-2030)
 Figure 50. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Saudi Arabia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 52. UAE Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 53. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2019-2030)
 Figure 54. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2019-2030)
 Figure 55. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2019-2030)
 Figure 56. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2019-2030)
 Figure 57. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2019-2030)
 Figure 58. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2019-2030)
 Figure 59. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain
 Figure 60. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Production Process
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Global Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Anti VEGF Ophthalmic Drug Market Research Report 2024
Global Fusion Protein Anti VEGF Ophthalmic Drugs Market Research Report 2024
Global Anti VEGT Drugs Market Research Report 2024
Global Anti VEGF Intravitreal Drugs Market Research Report 2024
Global Single target Anti VEGF Drugs Market Research Report 2024
Global Monoclonal Antibody VEGF Inhibitors Market Research Report 2024
Global Intravitreal Injection of Anti VEGF Drugs Market Research Report 2024
Global Anti VEGF Drugs for Angiogenesis related Disease Market Research Report 2024
Global VEGF A Inhibitor Market Research Report 2024
Global VEGF Inhibitors Market Research Report 2024
Global Ranibizumab Drugs and Biosimilars Market Research Report 2024
Global Anti angiogenic Ophthalmic Agent Market Research Report 2024
Global Anti VEGF Therapeutic Market Research Report 2025
Global Anti Vascular Endothelial Growth Factor Therapeutic Market Research Report 2025
Anti vascular Endothelial Growth Factor Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anti VEGF Therapy for Cancer Market Research Report 2024
Global Anti VEGF Drugs for the Treatment of Wet AMD Market Research Report 2024
Global VEGFA Antibody Market Research Report 2024
Global VEGF Inhibitors for Cancer Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions